Actinogen Medical (ASX: ACW)

Currency in AUD

Last close As at 22/09/2023


0.01 (50.00%)

Market capitalisation


Actinogen Medical is an ASX-listed Australian biotech developing its lead asset Xanamem, a specific and selective 11beta-HSD1 inhibitor designed to treat cognitive impairment (CI), which occurs in chronic neurodegenerative and neuropsychiatric diseases.

The unmet need in chronic neurocognitive disorders is tremendous due to the limited effectiveness of available treatment options. The Phase IIb portion of the XanaMIA trial will be key for validating the encouraging Xanamem data shown to date. The XanaCIDD study may also validate the drug’s potential for treating CI related to major depressive disorder.

Latest Insights

View More



Equity Analyst

Pooya Hemami

Analyst - Healthcare

Key Management

  • Dr Steven Gourlay

    CEO and MD

  • Michael Roberts

    Head of investor relations

Balance Sheet

Forecast net cash (A$m)


Forecast gearing ratio (%)


Share Price Performance

Price Performance
% 1M 3M 12M
Actual (24.3) (47.9) (62.7)
Relative (22.6) (48.4) (64.1)
52 week high/low A$0.1/A$0.0


Actinogen Medical’s lead asset, Xanamem, is a once-daily oral selective 11beta-HSD1 inhibitor, designed to cross the blood brain barrier and target excess brain cortisol, which has been associated with CI. The company is targeting two CI indications: for patients with mild CI in the early stages of Alzheimer’s disease (AD), and for patients with major depressive disorder. Positive clinical results in healthy adults demonstrated the drug’s initial efficacy, and a recent analysis of biomarker-positive patients using newly available plasma samples from the previous XanADu study in mild AD also showed clinical activity. Having received the requisite FDA authorisations, Actinogen plans to start its Phase IIb XanaMIA trial in patients with biomarker-confirmed early AD in H2 CY23. It started the XanaCIDD proof-of-concept Phase II trial in major depressive disorder in Q4 CY22 and plans to report top-line data in H1 CY24.

Y/E Jun Revenue (A$m) EBITDA (A$m) PBT (A$m) EPS (fd) (c) P/E (x) P/CF (x)
2021A 2.0 (3.5) (3.3) (0.236) N/A N/A
2022A 3.6 (9.1) (7.9) (0.460) N/A N/A
2023E 4.6 (10.1) (8.9) (0.494) N/A N/A
2024E 4.0 (37.3) (37.4) (1.856) N/A N/A




ASCO 2023 key takeaways



Machine learning in drug development

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free